PsychedelicNewsBreaks

FridayOct 02, 2020 1:28 pm

PsychedelicNewsBreaks – Cybin Corp. CEO Eyes Opportunity in Psychedelics Space, Organic IP Expansion

Cybin Corp., a Canada-based, life-science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, recently announced the appointment of Doug Drysdale as the company’s chief executive officer. Well recognized in the pharmaceutical space, Drysdale brings more than three decades of experience and a recognition of psychedelics as a major breakthrough in treating mental health conditions. Amid the recent strong push for research and commercialization in the psychedelics sector, Drysdale seeks to pursue emerging opportunities and pave the road for the company’s rapid growth. “I am beyond excited to be joining the Cybin team,” Drysdale stated in a recent article of…

Continue Reading

FridaySep 25, 2020 2:07 pm

PsychedelicNewsBreaks – Cybin Corp. Leverages Two-Pronged Approach to Target Psychedelic, Nutraceutical Sectors

Cybin Corp., a Canada-based life-science company, looks to benefit from its growing footprint in two billion-dollar markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see significant growth in the coming years. The global nutraceutical market was valued at $382.51 billion in 2019 and is expected to grow at an 8.3% compound annual growth rate (“CAGR”) over the next seven years. Meanwhile, the psychedelic drugs market is projected to reach $6.85 billion by 2027. Cybin’s business model is structured around two wholly owned divisions focused on targeting both promising spaces. A recent article discussing this reads, “Cybin is committed…

Continue Reading

ThursdaySep 24, 2020 3:51 pm

PsychedelicNewsBreaks – Pure Extract Technologies Inc. Eyes Functional Mushroom Sector for Initial Product Lines

Pure Extract Technologies, a private, plant-based extraction company poised to enter the commercial cannabis sector with a new vertical in functional mushrooms, has seized the opportunity to reveal its business development strategy (https://ibn.fm/6OXiR). A recent article discussing this reads, “As Pure Extracts positions itself to become the premier commercialization and manufacturing partner for functional companies going forward, the company plans to center its initial product lines on functional mushroom products. In its bid to do so, the company is applying for a Natural Health Products site license with Health Canada, which, once received, will enable Pure Extracts to begin producing clinical…

Continue Reading

FridaySep 18, 2020 1:36 pm

PsychedelicNewsBreaks – Pure Extract Technologies Inc. Poised as ‘Psychedelic Events Are Going Mainstream’

Pure Extract Technologies, a private, plant-based extraction company, is well positioned to partner with organizations eyeing development in both functional and psychedelic products. The company’s entry into functional medicinal mushrooms and collaboration in the psychedelic space look to be appropriately timed for a sector experiencing rising popularity and growing investment. An article discussing this highlights excerpts from a recent “Forbes” publication, titled “Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health” (http://ibn.fm/10yfG). The piece reads, “Psychedelics have been a mainstay for a millennia and appreciated in the counter-culture for decades. In 2020, whether consuming, investing, or…

Continue Reading

TuesdaySep 15, 2020 3:06 pm

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Issues Update Regarding Ongoing Disclosure Review

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) continues to work with the British Columbia Securities Commission to address an ongoing continuous disclosure review. According to the update, the company has arranged for the following since the review commenced: Filing of business acquisition reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp.; revocation of the initial cease trade order issued by the Commission on June 19, 2020; preparation of financial disclosure in connection with the acquisition of AltMed Capital Corp. (“AltMed”). The company expects this work to be concluded shortly, as…

Continue Reading

TuesdaySep 15, 2020 12:28 pm

PsychedelicNewsBreaks – Cybin Corp. CEO Discusses Milestones, Goals and Momentum in Exciting Emerging Industry

Cybin, a life-sciences company focused on advancing psychedelic and nutraceutical-based products, today announced that its CEO, Doug Drysdale, is featured in an exclusive audio interview with NetworkNewsWire (“NNW”) – a financial news and content distribution company and one of 50+ brands in the InvestorBrandNetwork (“IBN”). During the interview, Drysdale provides insight into Cybin’s 2020 milestones, near-term goals and its efforts to build on the momentum of an industry that continues to ramp up. “We have secured a source of GMP psilocybin API to support our initial clinical program, and we’ve initiated a program to synthesize our own proprietary API to…

Continue Reading

FridaySep 11, 2020 1:37 pm

PsychedelicNewsBreaks – Cybin Corp. Focused on Advancing New Products Amid Positive Research in Psychedelics

Cybin Corp., an exemplary Canada-based, life-science company focused on the development of pharmaceutical-grade psilocybin products, is at the forefront of change in an era open to exploring psychedelic treatment options where big pharma has failed. Started in the 1940s, but kiboshed in the 1960s with President Richard Nixon’s war on drugs, researchers have once again picked up the study of psychedelics in the treatment of mental health conditions. Research is showing positive results for many indications and disorders including depression, anxiety, PTSD, addictions, ADHD and more. A recent article discussing this reads, “Cybin believes that psychedelic substances derived from mushrooms…

Continue Reading

TuesdaySep 01, 2020 1:26 pm

PsychedelicNewsBreaks — Cybin Corp. Names Health-Care, M&A Expert as New Chief Executive Officer

Cybin Corp., a life-sciences company advancing psychedelic pharmaceuticals, has announced that Doug Drysdale has been appointed as CEO. With more than three decades of experience, Drysdale brings invaluable insight and expertise to his new role. In 2014 as a corporate director of a NASDAQ-listed pharmaceutical company, he led the company’s recapitalization efforts, raising an estimated $65 million. Consequently, he was appointment chairman and CEO and revamped the company’s management team and board of directors while also building a 220-person sales team — all within the first year. Ultimately he grew the company’s enterprise value exponentially from $80 million to around…

Continue Reading

ThursdayAug 27, 2020 2:36 pm

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) to Offer Esketamine for Treatment of Adults with MDD at Flagship Clinic

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced that it is expanding its rapid-onset treatment service for major depressive disorder (“MDD”). According to the update, Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic, the Canadian Rapid Treatment Centre of Excellence (“CRTCE”), starting in September 2020. Declared a breakthrough treatment for depression by the US Food and Drug Administration (“FDA”), esketamine was approved by Health Canada for the treatment of MDD in May 2020. “The availability of esketamine at the CRTCE provides tremendous opportunity for adults across Canada affected by treatment-resistant depression…

Continue Reading

WednesdayAug 26, 2020 2:48 pm

PsychedelicNewsBreaks – Cybin Corp. Poised Amid Groundbreaking Decision to Allow Psilocybin Therapy

Cybin Corp., an exemplary Canada-based life-science company focused on the development of pharmaceutical-grade psilocybin products, appears ideally positioned to leverage a milestone moment. Canada’s Minister of Health, the Honourable Patty Hajdu, recently approved the use of psilocybin therapy in the end-of-life treatment of four Canadians battling incurable cancer (http://ibn.fm/0BUOU), and this groundbreaking decision bodes well for companies such as Cybin, which are operating in the sector. The approval marks the first known, legal medical exemption for psilocybin use in Canada since the compound became illegal in the country in 1974. A recent article discussing this anticipates more applications through the exemption…

Continue Reading